Truist Securities analyst Srikripa Devarakonda reiterated a Buy rating and $70.00 price target on Cytokinetics (NASDAQ: CYTK).The analyst commented: "Ph3 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE